Holen Sie sich die Stockscreener-App
3.61
4.18%
0.145
Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten
KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
MIRA Pharmaceuticals' Novel Ketamine Drug Aces Preclinical Safety Tests, Phase I Trials Set for 2025 - StockTitan
Universe Pharmaceuticals Announces $15M Direct Offering with Warrants; Univest Securities Leading Placement - StockTitan
Fresh Tracks Therapeutics Faces Dissolution as Court Schedules Critical Delaware Hearing | FRTX Stock News - StockTitan
KalVista Pharmaceuticals Awards Inducement Stock Options to New Executive Team Members - StockTitan
Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 - StockTitan
X4 Pharmaceuticals Issues Major Stock Option Awards to New Employees at $0.371 Per Share - StockTitan
VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV - StockTitan
Terns Pharmaceuticals Grants 150,000 Share Options to New Employee at $6.24 - StockTitan
Titan Pharmaceuticals faces Nasdaq compliance issues - Investing.com
Titan Pharmaceuticals Faces Double Nasdaq Compliance Challenge Over Filing, Audit Issues | TTNP Stock News - StockTitan
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan
Lexicon Pharmaceuticals Appoints Former Eisai CEO Ivan Cheung to Board of Directors | LXRX Stock News - StockTitan
Melt Pharma's MELT-300 Shows Breakthrough Results in Phase 3 Sedation Trial | HROW Stock News - StockTitan
Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan
Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan
NeuroBo Pharma Rebrands as MetaVia, Advances $70M Cardiometabolic Pipeline | NRBO Stock News - StockTitan
Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study - StockTitan
Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan
TFF Pharmaceuticals Announces Complete Shutdown, Appoints Wind-Down Specialist as CEO | TFFP Stock News - StockTitan
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production - StockTitan
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan
Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan
Marinus (MRNS) Q3 Revenue Jumps 56%, Faces Setbacks in Clinical Trials - StockTitan
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
InMed Announces 1-for-20 Reverse Split to Maintain Nasdaq Listing - StockTitan
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan
InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan
Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - StockTitan
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - StockTitan
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - StockTitan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - StockTitan
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - StockTitan
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - StockTitan
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - StockTitan
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - StockTitan
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan
0.50%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):